DNA vaccines: an historical perspective and view to the future.
about
DNA vaccines: a simple DNA sensing matter?Therapeutic cancer vaccines: past, present, and futureMessenger RNA-based vaccines: progress, challenges, applicationsProgress and challenges toward the development of vaccines against avian infectious bronchitisHypothesis driven development of new adjuvants: short peptides as immunomodulatorsA global approach to HIV-1 vaccine developmentMelioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposesRabies Control and Treatment: From Prophylaxis to Strategies with Curative PotentialDNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvantDNA Vaccine Encoding the Chimeric Form of Schistosoma mansoni Sm-TSP2 and Sm29 Confers Partial Protection against Challenge InfectionEnhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013Protective efficacy of a human endogenous retrovirus envelope-coated, nonreplicable, baculovirus-based hemagglutin vaccine against pandemic influenza H1N1 2009.Molecular mechanisms for enhanced DNA vaccine immunogenicity.Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesProtective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa InfectionImmunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanomaComparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines.Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in MiceBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3.Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated formsToxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin A.The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus.Targeting DNA vaccines to myeloid cells using a small peptide.Use of a dual reporter plasmid to demonstrate Bactofection with an attenuated AroA(-) derivative of Pasteurella multocida B:2Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference.A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds.Vaccines and global health.Classification of current anticancer immunotherapiesTherapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptModulation of SIV and HIV DNA vaccine immunity by Fas-FasL signalingThe signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.
P2860
Q26859016-D6DFB8C6-9687-41A0-8F52-7BCF4626D2CDQ26863283-77FA90D1-0A28-4D5D-883D-D9952A441451Q27012738-4B22F9BF-3623-483B-82D9-DE01CF5C84E4Q27015837-2662844E-0ACA-4D44-8414-E06C37D85862Q27023844-4801CB13-986B-4D60-80FB-B3C2DF1CF34FQ27024614-EA724099-7792-4B7D-AC18-67F89E2993DEQ27305733-F93EE556-D139-4ED0-A26D-B518885E5857Q28076429-1442FF17-D217-45EE-8725-E28F7B9D8668Q28542668-64AF6DF5-E0B8-4AA1-BEAB-765981EE7969Q28547011-9D310339-98CD-4457-BF98-C36E8F84590BQ28654939-A2FD8C3D-7301-4DF6-AF44-0682E1CF86F1Q30355851-B6916ABC-479C-465C-8E8C-383FFDD2C49BQ30366743-2C51B004-4A69-4ACA-A9EE-8C948DAF6230Q30372481-FCD3957B-03B6-40E3-8783-F8917C51F3C7Q30427591-995228A2-79EB-43E8-A286-1A21E5722848Q33553646-1EB6AB18-4D62-40E9-943D-786A62B2E404Q33606137-34C591BC-FC8B-4BF9-AB31-34CBF69278C6Q33847809-636637CA-4A04-4E6A-A5DF-8A0D2FC99563Q33880398-AAED47B7-5519-4F06-B60C-D4102FB98862Q33955745-ABE1001B-E0A2-4A2C-A4B9-9B3174B6E0CFQ34046807-C3AA25CA-FEE1-4888-9FE1-35E502ED6A69Q34111151-6978A87D-3916-4A8E-ADD8-91BD8E00686BQ34271620-75CBE111-4DFD-48C8-B1CE-2DC670C60F51Q34428944-E9258CE2-4D11-4CCE-B178-550220291E9CQ34518201-CA93A299-62CF-4F43-9943-B6BAE1C88ED6Q34614953-175C63F2-3B3B-4B31-877C-2CD5D6CA92B3Q34633980-E12AB205-4683-4C78-B487-56F581745E8AQ34943809-DD72B59F-471E-42D8-B9E0-8A5F77058924Q34949822-396881AC-88A0-4B33-9FEB-C8C8D02831C5Q34971975-EB62729A-173D-4295-BC9C-C1BF66C67B27Q35089025-AD3C720A-DF7B-4924-81AC-D496A0F61E7BQ35099033-CEFEDEDC-9CC9-451C-AC3A-F4CCC7293CEBQ35137116-0A100F98-64D2-470E-BAA9-305673633B69Q35149637-93FF9075-21A3-48DC-820A-068A48F39FA0Q35193892-800F4674-F894-4938-AF51-E30F8696366BQ35232840-B4E12EC4-9669-432B-A5F1-830C688EBAA0Q35271066-6C524D52-A5FC-4156-854A-FB85B13596DAQ35600305-93888EC5-0B83-4BD9-9576-C19A48EFDF63Q35611969-4CB74AE2-ABEF-4AD6-9DDA-52F5A3B23F94Q35772032-FBFD4D19-B27E-42B1-BD5C-B0F9D2A670AE
P2860
DNA vaccines: an historical perspective and view to the future.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
DNA vaccines: an historical perspective and view to the future.
@en
DNA vaccines: an historical perspective and view to the future.
@nl
type
label
DNA vaccines: an historical perspective and view to the future.
@en
DNA vaccines: an historical perspective and view to the future.
@nl
prefLabel
DNA vaccines: an historical perspective and view to the future.
@en
DNA vaccines: an historical perspective and view to the future.
@nl
P2860
P1476
DNA vaccines: an historical perspective and view to the future.
@en
P2093
Margaret A Liu
P2860
P356
10.1111/J.1600-065X.2010.00980.X
P577
2011-01-01T00:00:00Z